MedTrace Logo

Does Whole Blood Adsorber During CPB Reduce Vasoactive Drugs Postoperatively in Endocarditis Patients Undergoing Valve Surgery?

NCT03945708 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-09-22

No results posted yet for this study

Summary

The study aims to investigate the effect of addition of an adsorber during cardio pulmonary bypassin patients with infective endocarditis undergoing valve surgery, and if it will decrease the use of vasoactive drugs postoperatively.

Conditions

  • Infective Endocarditis

Interventions

DEVICE

CytoSorb

Addition of a hemofilter to the cardiopulmonary bypass circuit

Sponsors & Collaborators

  • CytoSorbents, Inc

    collaborator INDUSTRY

  • Emma Hansson

    lead OTHER

Principal Investigators

  • Emma Hansson, MD PhD · Sahlgrenska University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-15
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03945708 on ClinicalTrials.gov